http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-065794-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-551 |
| filingDate | 2008-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2009-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-065794-A1 |
| titleOfInvention | PYRIMIDODIAZEPINAS REPLACED |
| abstract | The compounds are useful for the treatment or control of cell proliferation disorders, in particular oncological disorders. These compounds and the formulations containing them may be useful for the treatment or control of solid tumors, for example, breast, colon, lung or prostate tumors and other oncological disorders, for example non-Hodgkin lymphomas. Claim 1: A compound of the formula (1) in which R1 is a member selected from the group consisting of formulas (2) in which R2 is a member selected from the group consisting of straight or branched chain C1-5 alkyl , allyl, aryl, benzyl, heteroaryl, vinyl, heterocyclyl, C3-7 cycloalkyl optionally substituted with one or more C1-3 alkyl groups and C1-3 alkoxy-C1-3 alkyl; R3 and R4 are independently selected from the group consisting of hydrogen and methyl; or R2 and one of R3 and R4, together with the carbon and nitrogen to which they are attached, form a ring of five members; R5 and R6 are independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, hydroxymethyl, hydroxyethyl, cyclopropyl, chlorine, fluorine, bromine and iodine; or R5 and R6, together with the carbon to which they are attached, form uncyclopropyl or cyclobutyl; or R4 and R6, together with the carbons to which they are attached, form a five-member ring; or R3 and R5, together with the carbons to which they are attached, form a five-member ring; or R2 and one of R5 and R6, together with the carbon and the nitrogen to which they are attached, form a six-membered ring; R7 is a member chosen from the group consisting of hydrogen and lower alkyl; Y is a member selected from the group consisting of hydroxyl, di-C 1-3 alkyl, a six-membered heterocyclic ring containing one or two heteroatoms chosen from the group consisting of N and O, and NH-R9; R8 and R11 are independently selected from the group consisting of hydrogen, halogen, methyl and methoxy; R9 is a member selected from the group consisting of hydrogen, piperidinyl, N-benzyl-piperidinyl, N-C1-4 alkyl-piperidinyl, aryl, heteroaryl, C1-4 alkyl, tetrahydropyranyl, imidazolyl-C1-4 alkyl, amino and di- C1-3alkyl-C1-4alkyl, R10 is a member selected from the group consisting of hydrogen, hydroxyl and benzyloxy; and X is a member chosen from the group consisting of -C (O) NH- and -NHC (O) -; and pharmaceutically acceptable salts thereof. |
| priorityDate | 2007-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 45.